-
ANH News Beat (week 10/2023)
09 March 2023
Our weekly roundup of the latest natural and covid news in one place. Read the headlines or click on the links to find out more
-
Why misinformation bans are misinformed and dangerous
24 May 2023
In the light of this week’s Nobel Prize Summit, we explain why censorship is so dangerous, and why we need, in contrast, to broaden the scope of available information and foster dialogue and critical thinking
News / ANH Covid Zone / Health / Campaigns
-
ANH News Beat (week 13/2023)
30 March 2023
Our weekly roundup of the latest natural and covid news in one place. Read the headlines or click on the links to find out more
-
Peptide bioregulators presentation
18 July 2023
This presentation on peptide bioregulators is available to all Pathfinder members with an interest in their mechanisms and how they might help support our overall health
-
FEATURE: How the Nobel Prize Summit sold out on real science
12 June 2023
Despite noble ambitions, the Washington DC Nobel summit looked more like a breeding ground for AI-infused dogma and big corporate backed pseudoscience
News / ANH Covid Zone / Health / Campaigns
-
ANH News Beat (week 11/2023)
16 March 2023
Our weekly roundup of the latest natural and covid news in one place. Read the headlines or click on the links to find out more
-
Guest Article: Revealing the Dark Matter of Cancer
20 April 2023
Jerome Burne's latest article explores Mark Lintern's new theory of cancer development
-
Rob Verkerk to lead ANH both sides of the Atlantic
13 April 2023
With challenges to natural health and freedom mounting in the USA, the UK and Europe, ANH USA and International teams consolidate, with Verkerk as leader
-
PFAS campaign airs Down Under
20 July 2023
ANH founder, Rob Verkerk PhD joined Australian TNT Radio presenter, Dean Mackin, to discuss ANH-USA's PFAS in kale report and why PFAS chemicals pose such a serious threat to humanity and the environment
-
Are you up for taking Big Pharma's new 'skinny' jab?
16 March 2023
After a succession of Big Pharma failures for anti-obesity drugs, will Novo Nordisk's latest offering, that emerges from something of a dark cloud, be just another side effect ladened sticking plaster, or a boon for users and a cash cow for its manufacturer?